Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Complications of continuous intraperitoneal insulin infusion with an implantable pump.

van Dijk PR, Logtenberg SJ, Groenier KH, Haveman JW, Kleefstra N, Bilo HJ.

World J Diabetes. 2012 Aug 15;3(8):142-8. doi: 10.4239/wjd.v3.i8.142.

2.

Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion.

Logtenberg SJ, van Ballegooie E, Israêl-Bultman H, van Linde A, Bilo HJ.

Neth J Med. 2007 Feb;65(2):65-70.

3.

Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.

van Dijk PR, Logtenberg SJ, Groenier KH, Gans RO, Bilo HJ, Kleefstra N.

Diabetes Res Clin Pract. 2014 Nov;106(2):256-63. doi: 10.1016/j.diabres.2014.08.018. Epub 2014 Sep 30.

PMID:
25305134
4.

Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.

van Dijk PR, Logtenberg SJ, Groenier KH, Gans RO, Kleefstra N, Bilo HJ.

BMC Endocr Disord. 2014 Apr 7;14:30. doi: 10.1186/1472-6823-14-30.

5.

Surgical aspects and complications of continuous intraperitoneal insulin infusion with an implantable pump.

Haveman JW, Logtenberg SJ, Kleefstra N, Groenier KH, Bilo HJ, Blomme AM.

Langenbecks Arch Surg. 2010 Jan;395(1):65-71. doi: 10.1007/s00423-008-0437-9. Epub 2008 Dec 2.

PMID:
19048281
6.

Long-term safety and efficacy of programmable implantable insulin delivery systems.

Olsen CL, Liu G, Iravani M, Nguyen S, Khourdadjian K, Turner DS, Waxman K, Selam JL, Charles MA.

Int J Artif Organs. 1993 Dec;16(12):847-54.

PMID:
8175202
7.

Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII).

Micossi P, Bosi E, Cristallo M, Monti LD, Librenti MC, Petrella G, Galimberti G, Spotti D, Giudici G, Vergani C, et al.

Acta Diabetol Lat. 1986 Apr-Jun;23(2):155-64.

PMID:
3751449
8.

Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.

Oskarsson PR, Lins PE, Backman L, Adamson UC.

Diabetes Metab. 2000 Apr;26(2):118-24.

PMID:
10804326
9.

Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.

Lassmann-Vague V, Belicar P, Alessis C, Raccah D, Vialettes B, Vague P.

Diabet Med. 1996 Dec;13(12):1051-5.

PMID:
8973887
10.

Continuous intraperitoneal insulin infusion in the management of severely brittle diabetes--a metabolic and clinical comparison with intravenous infusion.

Husband DJ, Marshall SM, Walford S, Hanning I, Wright PD, Alberti KG.

Diabet Med. 1984 Jul;1(2):99-104.

PMID:
6242795
11.

Continuous intraperitoneal insulin infusion in patients with 'brittle' diabetes: favourable effects on glycaemic control and hospital stay.

DeVries JH, Eskes SA, Snoek FJ, Pouwer F, Van Ballegooie E, Spijker AJ, Kostense PJ, Seubert M, Heine RJ.

Diabet Med. 2002 Jun;19(6):496-501.

PMID:
12060062
12.

Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study.

Dufaitre-Patouraux L, Riveline JP, Renard E, Melki V, Belicar-Schaepelynck P, Selam JL, Guerci B, Millot L, Brun JM, Fermon C, Catargi B, Gin H, Jeandidier N, Lejeune PJ, Lassmann-Vague V.

Diabetes Metab. 2006 Nov;32(5 Pt 1):427-32.

PMID:
17110897
13.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
14.
15.

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.

Guerci B, Igau B, Ziegler O, Crea T, Fruchart JC, Drouin P, Fievet C.

Metabolism. 1996 Apr;45(4):430-4.

PMID:
8609827
17.

Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.

Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Bélicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group.

Diabetes Metab. 2003 Dec;29(6):602-7.

PMID:
14707889
18.

Clinical trial of programmable implantable insulin pump for type I diabetes.

Selam JL, Micossi P, Dunn FL, Nathan DM.

Diabetes Care. 1992 Jul;15(7):877-85.

PMID:
1516508
19.

After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.

van Dijk PR, Logtenberg SJ, Chisalita SI, Hedman CA, Groenier KH, Gans RO, Kleefstra N, Arnqvist HJ, Bilo HJ.

Growth Horm IGF Res. 2015 Dec;25(6):316-9. doi: 10.1016/j.ghir.2015.08.007. Epub 2015 Aug 28.

PMID:
26336814
20.

Supplemental Content

Support Center